A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Ogen Side Effects, and Drug Interactions - Estropipate
Ogen Side Effects, and Drug Interactions - Estropipate
SIDE EFFECTS
The following additional adverse reactions have been reported with estrogen
therapy (see WARNINGS regarding induction
of neoplasia, adverse effects on the fetus,
increased incidence of gallbladder disease, cardiovascular
disease, elevated blood
pressure, and hypercalcemia).
- Genitourinary System:
- Changes in vaginal bleeding
pattern and abnormal withdrawal
bleeding or flow: breakthrough bleeding,
spotting.
- Increase in size of uterine
leiomyomata.
- Vaginal candidiasis.
- Change in amount of cervical
secretion.
- Breast:
- Tenderness, enlargement.
- Gastrointestinal:
- Nausea, vomiting.
- Abdominal cramps, bloating.
- Cholestatic jaundice.
- Increased incidence of gallbladder disease.
- Skin:
- Chloasma or melasma that may persist when drug
is discontinued.
- Erythema multiforme.
- Erythema nodosum.
- Hemorrhagic eruption.
- Loss of scalp hair.
- Hirsutism.
- Eyes:
- Steepening of Corneal curvature.
- Intolerance to contact lens.
- Central Nervous Svstem:
- Headache, migraine.
- Mental depression.
- Chorea.
- Miscellaneous:
- Increase or decrease in weight.
- Reduced carbohydrate
tolerance.
- Aggravation of porphyria.
- Edema.
- Changes in libido.
DRUG INTERACTIONS
Drug/Laboratory Test Interactions.
1. Accelerated prothrombin
time, partial thromboplastin
time, and platelet aggregation time; increased platelet
count; increased factors II, VII antigen, VIII antigen,
VIII coagulant activity. IX, X, XII, VII- X complex, II- VII- X complex.
and beta- thromboglobulin; decreased levels of anti- factor Xa and antithrombin
III, decreased antithrombin III activity; increased levels of fibrinogen
and fibrinogen activity:
increased plasminogen
antigen and activity.
2. Increased thyroid-binding globulin (TBG) leading to increased circulating
total thyroid hormone,
as measured by protein- bound
iodine (PBI), T4 levels (by column or by radioimmunoassay)
or T3 levels by radioimmunoassay. T3 resin uptake
is decreased, reflecting the elevated TBG. Free T4 and free
T3 concentrations are unaltered.
3. Other binding proteins may be elevated in serum,
i.e., corticosteroid binding globulin (CBG), sex
hormone- binding globulin (SHBG), leading to increased circulating corticosteroids
and sex steroids respectively.
Free or biologically active hormone
concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/
renin substrate,
alpha-l-antitrypsin, ceruloplasmin).
4. Increased plasma HDL and
HDL-2 subfraction concentrations, reduced LDL cholesterol
concentration, increased
triglycerides levels.
5. Impaired glucose tolerance.
6. Reduced response to metyrapone test.
7. Reduced serum folate concentration.
top
